bit.bio raised $25 million in a Series D aimed at scaling its human cell models, targeting industry-standard status for drug discovery use. The funding is intended to expand model throughput and capabilities as biopharma increasingly seeks better human-relevant systems for mechanism work and candidate selection. The company’s positioning emphasizes practical utility—human cell models designed for research and translation—rather than purely academic assays. This financing adds to ongoing investment in preclinical platforms as developers face attrition pressure in late discovery and early clinical stages. In the current biotech funding environment, platform companies with scalable, standardized assets are increasingly valued because they can reduce variability and improve decision-making speed. The round underscores continued capital interest in translational biology infrastructure that can be reused across drug programs.